Company Profile
COR insider trades (13 months) →Today's multi-factor rank: 141 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
Cencora, Inc. (COR) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 8-K | 2026-08-14 | View filing ↗ |
| 8-K | 2026-08-12 | View filing ↗ |
| 8-K | 2026-08-05 | View filing ↗ |
| 11-K | 2026-06-18 | View filing ↗ |
| 8-K | 2026-06-15 | View filing ↗ |
| SD | 2026-05-29 | View filing ↗ |
| 8-K | 2026-05-06 | View filing ↗ |
| 8-K | 2026-03-23 | View filing ↗ |
| 8-K | 2026-03-17 | View filing ↗ |
| 8-K | 2026-03-06 | View filing ↗ |
Company and Executive Profile
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Dr. Robert P. Mauch Ph.D., PharmD | President, CEO & Director | 58 | 6.26M |
| Ms. Elizabeth S. Campbell J.D. | Executive VP & Chief Legal Officer | 50 | 2.28M |
| Mr. James F. Cleary Jr. | Advisor | 62 | 2.72M |
| Ms. Silvana Battaglia | Advisor | 57 | 1.96M |
| Ms. Eva C. Boratto | Executive VP & CFO | 58 | - |
| Mr. Lazarus Krikorian | Senior VP, Chief Accounting Officer & Corporate Controller | 60 | - |
| Mr. Pawan Singh Verma | Executive VP and Chief Data & Information Officer | 48 | - |
| Mr. Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | - | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.